In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 47 days of free consultation

 

Circulating biomarkers of cell adhesion in relation to clinical outcomes in patients with chronic heart failure: the Bio-SHiFT study

Session Is inflammation really important in heart failure?

Speaker Elke Bouwens

Congress : ESC Congress 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure - Epidemiology, Prognosis, Outcome
  • Session type : Rapid Fire Abstracts
  • FP Number : 5948

Authors : E Bouwens (Rotterdam,NL), VJ Van Den Berg (Rotterdam,NL), KM Akkerhuis (Rotterdam,NL), S Baart (Rotterdam,NL), K Caliskan (Rotterdam,NL), JJ Brugts (Rotterdam,NL), H Mouthaan (Uppsala,SE), J Van Ramshorst (Alkmaar,NL), T Germans (Alkmaar,NL), VA Umans (Alkmaar,NL), H Boersma (Rotterdam,NL), I Kardys (Rotterdam,NL)

Authors:
E Bouwens1 , VJ Van Den Berg1 , KM Akkerhuis1 , S Baart1 , K Caliskan1 , JJ Brugts1 , H Mouthaan2 , J Van Ramshorst3 , T Germans3 , VA Umans3 , H Boersma1 , I Kardys1 , 1Erasmus Medical Center, Cardiology - Rotterdam - Netherlands (The) , 2Olink Proteomics - Uppsala - Sweden , 3Medical Center Alkmaar, Cardiology - Alkmaar - Netherlands (The) ,

Citation:

Background: Cardiovascular inflammation and vascular endothelial dysfunction are present in chronic heart failure (CHF), and cellular adhesion molecules are considered to play a key role in these mechanisms. The temporal patterns of the blood biomarkers involved could provide further insights into these processes.

Purpose: We aimed to evaluate the prognostic value of the temporal patterns of blood biomarkers of cell adhesion in stable patients with CHF.

Methods: In 263 patients, a median of 9 (IQR: 5-10) serial, tri-monthly blood samples were collected during a median follow-up of 2.2 (IQR: 1.4-2.5) years. The composite primary endpoint (PE) of cardiovascular mortality, HF-hospitalization, heart transplantation and LVAD was reached in 70 patients. For efficiency, we selected all baseline samples, the two samples closest to a PE, and the last sample available for event-free patients. Thus, in 567 samples we measured twelve biomarkers of cell adhesion using the Olink Proteomics Cardiovascular III multiplex assay. Associations between biomarkers and first PE were investigated by combining linear mixed effect models and Cox regression (so-called joint model).

Results: Median age was 68 (IQR: 59-76) years, with 72% men and 74% NYHA class I-II. Levels of CD93 (Complement component C1q receptor), CDH5 (VE cadherin), CHI3L1 (Chitinase-3-like protein 1), EPHB4 (Ephrin type-B receptor 4) and JAM-A (Junctional adhesion molecule A) differed at baseline already. The average biomarker evolutions of these markers, and additionally of ICAM-2 (Intercellular adhesion molecule-2), showed different patterns in patients approaching the PE versus those who remained event-free (Figure 1). Repeatedly measured levels of these biomarkers were independently associated with the PE. Corresponding HRs [95% CI] per 1SD increase in log2 level (arbitrary unit) were: CD93: 1.85 [1.29-2.70], CDH5: 1.72 [1.23-2.44], CHI3L1: 2.45 [1.73-3.56], EPHB4: 1.83 [1.33-2.55], ICAM2: 1.74 [1.24-2.46] and JAM-A: 2.07 [1.39-3.18], adjusted for clinical characteristics (age, sex, diabetes, atrial fibrillation, baseline NYHA class, diuretics, systolic blood pressure and eGFR).

Conclusion: CD93, CDH5, CHI3L1, EPHB4, ICAM2 and JAM-A show different patterns as adverse events approach in CHF patients, and their temporal patterns strongly predict clinical outcome. These findings demonstrate the incremental value of repeated measurements of biomarkers of cell adhesion in stable patients with CHF.

Figure 1: Average temporal patterns of cell adhesion biomarkers during follow-up.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are